Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.

Molecular medicine reports - 1 Aug 2018

Jing Changwen, Mao Xuhua, Wang Zhuo, Sun Kejing, Ma Rong, Wu Jianzhong, Cao Haixia

Abstract excerpt

In recent years, the incidence of non‑small cell lung cancer (NSCLC) has become the highest lethal rate of cancer worldwide. Molecular assays of EGFR, KRAS, BRAF, NRAS, PIK3CA and Her‑2 are widely used to guide individualized treatment in NSCLC patients. Somatic mutations in 112 NSCLC patients, including 7 oncogenic driver genes, were detected by Iontorrent personal genome machine (PGM). Sanger sequencing was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to High-Throughput Nucleotide Sequencing

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, ErbB-2

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 29956783
DOI: 10.3892/mmr.2018.9210
PMCID: PMC6072231

Genes

EGFR
BRAF
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.PMID 29956783Read ↗

[Advances in Diagnosis and Targeted Therapy of G719X/L861Q/S768I Mutant Non-small Cell Lung Cancer].Semantic proximity Read ↗

Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.Semantic proximity Read ↗

Clinical mutational profiling of 1006 lung cancers by next generation sequencingSemantic proximity Read ↗

Next-Generation Sequencing in Lung Cancers-A Single-Center Experience in Taiwan.Semantic proximity Read ↗

Epidermal growth factor receptor mutation testing: From conventional to real-time diagnosis of lung cancer.Semantic proximity Read ↗

The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China.Semantic proximity Read ↗

Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine.Semantic proximity Read ↗

[Advances on driver oncogenes of non-small cell lung cancer].Semantic proximity Read ↗

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare HospitalSemantic proximity Read ↗

Clinical next-generation sequencing in patients with non-small cell lung cancer.Semantic proximity Read ↗

Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory.Semantic proximity Read ↗

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.